By Barbara Obstoj-Cardwell. Editor
Bernstein analyst Tim Anderson and team wonder if Pfizer winning the bidding war for Medivation with its $14 billion offer ( announced last Monday) is “something to be proud of,” reported Barron’s magazine.
At first pass, paying $80+/share for a stock that was trading in the $30′s just a few months ago feels pricey. What Pfizer gains is Medivation’s cut of Xtandi, and a Phase III PARP inhibitor, talazoparib, that Medivation itself recently bought from BioMarin. Medivation's prostate cancer treatment Xtandi generates close to $2 billion in annual sales and is projected to earn $4.8 billion in annual sales by 2020.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze